Two patients with refractory ovarian cancer treated at 210 mg achieved SD and remained on study treatment at full dosing for six and eight cycles prior to coming off study; one of these patients had a 20% reduction in cancer antigen 125 (CA125). This evidence concerns the gene MUC16 and ovarian carcinoma.